A Phase II Study of Stereotactic Body Radiotherapy (SBRT) for Low-Intermediate-High Risk Prostate Cancer Using Helical Tomotherapy: Dose-volumetric parameters predicting early toxicity

Endpoint: To assess early urinary (GU) and rectal (GI) toxicities after helical tomotherapy Stereotactic Body Radiation Therapy (SBRT), and to determine their predictive factors.Methods: Since May 2012 forty-five prostate cancer patients were treated with 8 fractions of 5.48 (low risk, 29%) or 5.65...

Full description

Bibliographic Details
Main Authors: Victor A Macias, Manuel eBlanco, Inmaculada eBarrera, Rafael eGarcia
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-11-01
Series:Frontiers in Oncology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00336/full
id doaj-ecefcd8734f3455dbc02953608bd436c
record_format Article
spelling doaj-ecefcd8734f3455dbc02953608bd436c2020-11-25T01:08:26ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2014-11-01410.3389/fonc.2014.00336114727A Phase II Study of Stereotactic Body Radiotherapy (SBRT) for Low-Intermediate-High Risk Prostate Cancer Using Helical Tomotherapy: Dose-volumetric parameters predicting early toxicityVictor A Macias0Manuel eBlanco1Inmaculada eBarrera2Rafael eGarcia3Salamanca University HospitalSalamanca University HospitalUniversity of SalamancaIMO GroupEndpoint: To assess early urinary (GU) and rectal (GI) toxicities after helical tomotherapy Stereotactic Body Radiation Therapy (SBRT), and to determine their predictive factors.Methods: Since May 2012 forty-five prostate cancer patients were treated with 8 fractions of 5.48 (low risk, 29%) or 5.65 Gy (intermediate-high risk, 71%) on alternative days over 2.5 weeks. The exclusion criteria were: Gleason score 9-10, PSA >40 ng/mL, cT3b-4, IPSS ≥20 and history of acute urinary retention. During the follow-up a set of potential prognostic factors was correlated with urinary or rectal toxicity.Results: The median follow-up was 13.8 months (2-25 months). There were no grade ≥3 toxicities. Acute grade 2 GU complications were found in a 22.7% of men, but in 2.3% of patients at 1 month, 0% at 6 months and 0% at 12 months. The correspondent figures for grade 2 GI toxicities were: 20.4% (acute), 2.3% (1 month), 3.6% (6 months) and 5% (12 months). Acute GI toxicity was significantly correlated with the rectal volume (>15 cm3) receiving 28 Gy, only when expressed as absolute volume. The age (>72 years old) was a predictor of GI toxicity after 1 month of treatment. No correlation was found, however, between urinary toxicity and the other analyzed variables. IPSS increased significantly at the time of the last fraction and within the 1st month, returning to the baseline at 6th month. Urinary-related quality of life (IPSS question 8 score), it was not significantly worsen during radiotherapy returning to the baseline levels 1 month after the treatment. At 12 months follow-up patient’s perception of their urinary function improved significantly in comparison with the baseline.Conclusion: Our scheme of 8 fractions on alternative days delivered using helical tomotherapy is well tolerated. We recommend using actual volume instead of percentual volume in the treatment planning, and not to exceed 15 cm3 of rectal volume receiving ≥25 Gy in order to diminish acute GI toxicity.http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00336/fullprostate cancerstereotactic body radiation therapytomotherapyipssPredictors ToxicityCommon Toxicity Criteria (CTC)
collection DOAJ
language English
format Article
sources DOAJ
author Victor A Macias
Manuel eBlanco
Inmaculada eBarrera
Rafael eGarcia
spellingShingle Victor A Macias
Manuel eBlanco
Inmaculada eBarrera
Rafael eGarcia
A Phase II Study of Stereotactic Body Radiotherapy (SBRT) for Low-Intermediate-High Risk Prostate Cancer Using Helical Tomotherapy: Dose-volumetric parameters predicting early toxicity
Frontiers in Oncology
prostate cancer
stereotactic body radiation therapy
tomotherapy
ipss
Predictors Toxicity
Common Toxicity Criteria (CTC)
author_facet Victor A Macias
Manuel eBlanco
Inmaculada eBarrera
Rafael eGarcia
author_sort Victor A Macias
title A Phase II Study of Stereotactic Body Radiotherapy (SBRT) for Low-Intermediate-High Risk Prostate Cancer Using Helical Tomotherapy: Dose-volumetric parameters predicting early toxicity
title_short A Phase II Study of Stereotactic Body Radiotherapy (SBRT) for Low-Intermediate-High Risk Prostate Cancer Using Helical Tomotherapy: Dose-volumetric parameters predicting early toxicity
title_full A Phase II Study of Stereotactic Body Radiotherapy (SBRT) for Low-Intermediate-High Risk Prostate Cancer Using Helical Tomotherapy: Dose-volumetric parameters predicting early toxicity
title_fullStr A Phase II Study of Stereotactic Body Radiotherapy (SBRT) for Low-Intermediate-High Risk Prostate Cancer Using Helical Tomotherapy: Dose-volumetric parameters predicting early toxicity
title_full_unstemmed A Phase II Study of Stereotactic Body Radiotherapy (SBRT) for Low-Intermediate-High Risk Prostate Cancer Using Helical Tomotherapy: Dose-volumetric parameters predicting early toxicity
title_sort phase ii study of stereotactic body radiotherapy (sbrt) for low-intermediate-high risk prostate cancer using helical tomotherapy: dose-volumetric parameters predicting early toxicity
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2014-11-01
description Endpoint: To assess early urinary (GU) and rectal (GI) toxicities after helical tomotherapy Stereotactic Body Radiation Therapy (SBRT), and to determine their predictive factors.Methods: Since May 2012 forty-five prostate cancer patients were treated with 8 fractions of 5.48 (low risk, 29%) or 5.65 Gy (intermediate-high risk, 71%) on alternative days over 2.5 weeks. The exclusion criteria were: Gleason score 9-10, PSA >40 ng/mL, cT3b-4, IPSS ≥20 and history of acute urinary retention. During the follow-up a set of potential prognostic factors was correlated with urinary or rectal toxicity.Results: The median follow-up was 13.8 months (2-25 months). There were no grade ≥3 toxicities. Acute grade 2 GU complications were found in a 22.7% of men, but in 2.3% of patients at 1 month, 0% at 6 months and 0% at 12 months. The correspondent figures for grade 2 GI toxicities were: 20.4% (acute), 2.3% (1 month), 3.6% (6 months) and 5% (12 months). Acute GI toxicity was significantly correlated with the rectal volume (>15 cm3) receiving 28 Gy, only when expressed as absolute volume. The age (>72 years old) was a predictor of GI toxicity after 1 month of treatment. No correlation was found, however, between urinary toxicity and the other analyzed variables. IPSS increased significantly at the time of the last fraction and within the 1st month, returning to the baseline at 6th month. Urinary-related quality of life (IPSS question 8 score), it was not significantly worsen during radiotherapy returning to the baseline levels 1 month after the treatment. At 12 months follow-up patient’s perception of their urinary function improved significantly in comparison with the baseline.Conclusion: Our scheme of 8 fractions on alternative days delivered using helical tomotherapy is well tolerated. We recommend using actual volume instead of percentual volume in the treatment planning, and not to exceed 15 cm3 of rectal volume receiving ≥25 Gy in order to diminish acute GI toxicity.
topic prostate cancer
stereotactic body radiation therapy
tomotherapy
ipss
Predictors Toxicity
Common Toxicity Criteria (CTC)
url http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00336/full
work_keys_str_mv AT victoramacias aphaseiistudyofstereotacticbodyradiotherapysbrtforlowintermediatehighriskprostatecancerusinghelicaltomotherapydosevolumetricparameterspredictingearlytoxicity
AT manueleblanco aphaseiistudyofstereotacticbodyradiotherapysbrtforlowintermediatehighriskprostatecancerusinghelicaltomotherapydosevolumetricparameterspredictingearlytoxicity
AT inmaculadaebarrera aphaseiistudyofstereotacticbodyradiotherapysbrtforlowintermediatehighriskprostatecancerusinghelicaltomotherapydosevolumetricparameterspredictingearlytoxicity
AT rafaelegarcia aphaseiistudyofstereotacticbodyradiotherapysbrtforlowintermediatehighriskprostatecancerusinghelicaltomotherapydosevolumetricparameterspredictingearlytoxicity
AT victoramacias phaseiistudyofstereotacticbodyradiotherapysbrtforlowintermediatehighriskprostatecancerusinghelicaltomotherapydosevolumetricparameterspredictingearlytoxicity
AT manueleblanco phaseiistudyofstereotacticbodyradiotherapysbrtforlowintermediatehighriskprostatecancerusinghelicaltomotherapydosevolumetricparameterspredictingearlytoxicity
AT inmaculadaebarrera phaseiistudyofstereotacticbodyradiotherapysbrtforlowintermediatehighriskprostatecancerusinghelicaltomotherapydosevolumetricparameterspredictingearlytoxicity
AT rafaelegarcia phaseiistudyofstereotacticbodyradiotherapysbrtforlowintermediatehighriskprostatecancerusinghelicaltomotherapydosevolumetricparameterspredictingearlytoxicity
_version_ 1725182659386146816